In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.
Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
A "watch-and-wait" strategy might be the best option for some women with early-stage, low-risk breast cancer. Photo by Adobe Stock/HealthDay News A "watch-and-wait" strategy might be the best option ...
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 Ductal carcinoma in situ (DCIS) is routinely treated with ...
Please provide your email address to receive an email when new articles are posted on . Results showed a lower 2-year cumulative rate of invasive ipsilateral breast cancer among patients assigned ...
SAN ANTONIO – Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ...
SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback